These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

327 related items for PubMed ID: 19694578

  • 1. Receptor-binding, biodistribution, dosimetry, and micro-SPECT/CT imaging of 111In-[DTPA(1), Lys(3), Tyr(4)]-bombesin analog in human prostate tumor-bearing mice.
    Ho CL, Chen LC, Lee WC, Chiu SP, Hsu WC, Wu YH, Yeh CH, Stabin MG, Jan ML, Lin WJ, Lee TW, Chang CH.
    Cancer Biother Radiopharm; 2009 Aug; 24(4):435-43. PubMed ID: 19694578
    [Abstract] [Full Text] [Related]

  • 2. Selection of optimal chelator improves the contrast of GRPR imaging using bombesin analogue RM26.
    Mitran B, Varasteh Z, Selvaraju RK, Lindeberg G, Sörensen J, Larhed M, Tolmachev V, Rosenström U, Orlova A.
    Int J Oncol; 2016 May; 48(5):2124-34. PubMed ID: 26983776
    [Abstract] [Full Text] [Related]

  • 3. In vitro and in vivo evaluation of a 64Cu-labeled NOTA-Bn-SCN-Aoc-bombesin analogue in gastrin-releasing peptide receptor expressing prostate cancer.
    Craft JM, De Silva RA, Lears KA, Andrews R, Liang K, Achilefu S, Rogers BE.
    Nucl Med Biol; 2012 Jul; 39(5):609-16. PubMed ID: 22261146
    [Abstract] [Full Text] [Related]

  • 4. microPET and autoradiographic imaging of GRP receptor expression with 64Cu-DOTA-[Lys3]bombesin in human prostate adenocarcinoma xenografts.
    Chen X, Park R, Hou Y, Tohme M, Shahinian AH, Bading JR, Conti PS.
    J Nucl Med; 2004 Aug; 45(8):1390-7. PubMed ID: 15299066
    [Abstract] [Full Text] [Related]

  • 5. A new high affinity technetium analogue of bombesin containing DTPA as a pharmacokinetic modifier.
    Lin KS, Luu A, Baidoo KE, Hashemzadeh-Gargari H, Chen MK, Pili R, Pomper M, Carducci M, Wagner HN.
    Bioconjug Chem; 2004 Aug; 15(6):1416-23. PubMed ID: 15546210
    [Abstract] [Full Text] [Related]

  • 6. Evaluation and comparison of a new DOTA and DTPA-bombesin agonist in vitro and in vivo in low and high GRPR expressing prostate and breast tumor models.
    Pujatti PB, Foster JM, Finucane C, Hudson CD, Burnet JC, Pasqualoto KFM, Mengatti J, Mather SJ, de Araújo EB, Sosabowski JK.
    Appl Radiat Isot; 2015 Feb; 96():91-101. PubMed ID: 25479439
    [Abstract] [Full Text] [Related]

  • 7. Synthesis and evaluation of bombesin derivatives on the basis of pan-bombesin peptides labeled with indium-111, lutetium-177, and yttrium-90 for targeting bombesin receptor-expressing tumors.
    Zhang H, Chen J, Waldherr C, Hinni K, Waser B, Reubi JC, Maecke HR.
    Cancer Res; 2004 Sep 15; 64(18):6707-15. PubMed ID: 15374988
    [Abstract] [Full Text] [Related]

  • 8. MicroPET imaging of a gastrin-releasing peptide receptor-positive tumor in a mouse model of human prostate cancer using a 64Cu-labeled bombesin analogue.
    Rogers BE, Bigott HM, McCarthy DW, Della Manna D, Kim J, Sharp TL, Welch MJ.
    Bioconjug Chem; 2003 Sep 15; 14(4):756-63. PubMed ID: 12862428
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Pre-clinical evaluation of [(111)In-DTPA-Pro(1), Tyr(4)]bombesin, a new radioligand for bombesin-receptor scintigraphy.
    Breeman WA, De Jong M, Bernard BF, Kwekkeboom DJ, Srinivasan A, van der Pluijm ME, Hofland LJ, Visser TJ, Krenning EP.
    Int J Cancer; 1999 Nov 26; 83(5):657-63. PubMed ID: 10521803
    [Abstract] [Full Text] [Related]

  • 11. Synthesis and in vitro and in vivo evaluation of hypoxia-enhanced 111In-bombesin conjugates for prostate cancer imaging.
    Zhou Z, Wagh NK, Ogbomo SM, Shi W, Jia Y, Brusnahan SK, Garrison JC.
    J Nucl Med; 2013 Sep 26; 54(9):1605-12. PubMed ID: 23896558
    [Abstract] [Full Text] [Related]

  • 12. Preclinical comparison of (111)In-labeled DTPA- or DOTA-bombesin analogs for receptor-targeted scintigraphy and radionuclide therapy.
    Breeman WA, de Jong M, Erion JL, Bugaj JE, Srinivasan A, Bernard BF, Kwekkeboom DJ, Visser TJ, Krenning EP.
    J Nucl Med; 2002 Dec 26; 43(12):1650-6. PubMed ID: 12468515
    [Abstract] [Full Text] [Related]

  • 13. Dual-Modality Imaging of Prostate Cancer with a Fluorescent and Radiogallium-Labeled Gastrin-Releasing Peptide Receptor Antagonist.
    Zhang H, Desai P, Koike Y, Houghton J, Carlin S, Tandon N, Touijer K, Weber WA.
    J Nucl Med; 2017 Jan 26; 58(1):29-35. PubMed ID: 27516447
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Molecular imaging of gastrin-releasing peptide receptor-positive tumors in mice using 64Cu- and 86Y-DOTA-(Pro1,Tyr4)-bombesin(1-14).
    Biddlecombe GB, Rogers BE, de Visser M, Parry JJ, de Jong M, Erion JL, Lewis JS.
    Bioconjug Chem; 2007 Jan 26; 18(3):724-30. PubMed ID: 17378600
    [Abstract] [Full Text] [Related]

  • 16. In vitro and in vivo evaluation of 64Cu-labeled SarAr-bombesin analogs in gastrin-releasing peptide receptor-expressing prostate cancer.
    Lears KA, Ferdani R, Liang K, Zheleznyak A, Andrews R, Sherman CD, Achilefu S, Anderson CJ, Rogers BE.
    J Nucl Med; 2011 Mar 26; 52(3):470-7. PubMed ID: 21321264
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Preclinical and first clinical experience with the gastrin-releasing peptide receptor-antagonist [⁶⁸Ga]SB3 and PET/CT.
    Maina T, Bergsma H, Kulkarni HR, Mueller D, Charalambidis D, Krenning EP, Nock BA, de Jong M, Baum RP.
    Eur J Nucl Med Mol Imaging; 2016 May 26; 43(5):964-973. PubMed ID: 26631238
    [Abstract] [Full Text] [Related]

  • 19. PEGylation of (99m)Tc-labeled bombesin analogues improves their pharmacokinetic properties.
    Däpp S, García Garayoa E, Maes V, Brans L, Tourwé DA, Müller C, Schibli R.
    Nucl Med Biol; 2011 Oct 26; 38(7):997-1009. PubMed ID: 21982571
    [Abstract] [Full Text] [Related]

  • 20. Preclinical pharmacokinetic, biodistribution, imaging and therapeutic efficacy of (177)Lu-Labeled glycated bombesin analogue for gastrin-releasing peptide receptor-positive prostate tumor targeting.
    Lim JC, Cho EH, Kim JJ, Choi SM, Lee SY, Nam SS, Park UJ, Park SH.
    Nucl Med Biol; 2015 Mar 26; 42(3):234-41. PubMed ID: 25498002
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.